EN DE
Watch OrganiGram Holdings Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

OrganiGram Holdings Inc (OGI) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of OrganiGram Holdings Inc stock C$0.51, price C$1.25, that is 59.2% below the price, quality 35 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CA · ISIN CA68617J1003

OH OrganiGram Holdings Inc logo Thin data Nov 8, 2026

OrganiGram Holdings Inc

OGI · TO
Very expensive, weak quality

Our calculation puts a fair price 59% below what the stock costs today.

Highly profitable · 28.0% net margin (TTM)
Low debt
Costs just 2.1 times its yearly profit.
Expensive Growth (revenue 5y +24.5 %/yr in CAD)
Mixed vs. peers (7/12)
Moderate moat 47/100 · thin data
Fair value C$0.5100 · Strongly overvalued
Quality 35/100
Negative free cash flow
Thin data
Watch OrganiGram Holdings Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

C$14.44 C$1.23 Fair Value C$0.5100 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range C$1.23 – C$14.44 · fair‑value band C$0.3400 – C$0.6400 · the C$1.25 price screens above the C$0.5100 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow OrganiGram Holdings in your weekly email

Every Wednesday you see whether OrganiGram Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada.

Show moreShow less

It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands.

The company also engages in the wholesale shipping of cannabis plant cuttings and dried flowers to other licensed producers. It sells cannabis products to wholesale and retail channels in the recreational and medical cannabis regimes, as well as through online.

Organigram Global Inc. was formerly known as Organigram Holdings Inc. and changed its name to Organigram Global Inc. in March 2025. The company is headquartered in Toronto, Canada.

Stock analysis

OrganiGram Holdings Inc (OGI) currently trades at C$1.25, while our model-based Fair Value estimate is C$0.5100, 59% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: C$0.3400 (bear) to C$0.6400 (bull), the price of C$1.25 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

OrganiGram Holdings Inc reported revenue of C$259M in FY2025 versus C$79.2M in FY2021, a compound +34.5%/yr. Reported net income was −C$24.8M in FY2025.

Key figures

Market cap C$174M (≈ $123M) Micro · P/E ratio 2.1 · P/S ratio 0.56 · EPS (TTM) C$0.6000 · Net margin 28.0% · Return on equity 17.6% · Return on assets (EBIT) −26.0% (5-year average) · Operating margin 5.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).

What moves the price

The share trades about 57% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −59%, OGI screens richer than that median.

Fair Value models

Bear C$0.3400 Fair Value C$0.5100 Bull C$0.6400
Price C$1.25 · Downside -59.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (C$0.6000 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) C$0.3400 C$0.5100 C$0.6400 55
All 1 models by family
Asset-Based
NCAV (Graham) C$0.3400 C$0.5100 C$0.6400 55

Open the full fair value analysis →

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 7
How much profit the company makes from its sales and capital
Quality Growth 77
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 59
Debt, balance sheet and risk of trouble
Investment 92
Does it invest with discipline instead of growing at any price?
Low Volatility 3
How calm the share price moves, does not count
Price momentum 13
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 5
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+62.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.5%
Start year 2020 (pandemic). Over 10 years: +74.6% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+108.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−167.6% (2020) → −34.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

OGI screens overvalued: fair value 59% below the price. Compare with Merck KGaA →

Compare OrganiGram Holdings Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 35 · Bottom 25%
Fair Value upside −59.2% · Bottom 25%
Profitability
Return on equity (12 months) 17.6% · Top 25%
Return on assets −4.4% · Bottom 25%
Net margin (12 months) 28.0% · Top 25%
Operating margin (12 months) 5.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) 49.4% · Top 25%
Balance sheet
Debt / equity 0.20× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 2.1× · Cheapest 25%
P/B 0.50× · Cheapest 25%
P/S (12 months) 0.56× · Cheapest 25%
EV/EBITDA 9.7× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)70 · sector 29
HEALTH (low debt)90 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs OGI
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs OGI
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs OGI
Haleon plc HLN $9.14 $8.61 −6% vs OGI
Merck KGaA MRK €148.75 €109.18 −27% vs OGI
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs OGI
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs OGI
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs OGI
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs OGI
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs OGI

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

OrganiGram Holdings Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "OrganiGram Holdings Inc Fair Value". https://www.fairvalue-calculator.com/stock/OGI

Frequently asked questions

Is OrganiGram Holdings Inc (OGI) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of C$0.5100 versus a price of C$1.25, about 59% lower (overvalued).
What is the fair value of OGI?
Our model-based fair value for OrganiGram Holdings Inc is C$0.5100 (as of Nov 8, 2026), built from audited fundamentals. The current price: C$1.25.
What is the quality score of OGI?
OrganiGram Holdings Inc has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for OrganiGram Holdings Inc (OGI)?
Our model-based price target is the fair value of C$0.5100 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario C$0.3400, optimistic scenario C$0.6400. It is a calculation from audited fundamentals, not an analyst target.
What is the OrganiGram Holdings Inc stock forecast for 2026?
Our models put fair value at C$0.5100, about 59% lower versus a price of C$1.25 (overvalued). Cautious scenario C$0.3400, optimistic scenario C$0.6400. The calculation is refreshed regularly with new filings.
What is the revenue of OrganiGram Holdings Inc (OGI)?
OrganiGram Holdings Inc reported trailing-twelve-month revenue of about C$309M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of OrganiGram Holdings Inc (OGI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For OrganiGram Holdings Inc it is C$0.5100 per share (as of Nov 8, 2026), against a price of C$1.25. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is OrganiGram Holdings Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, OGI trades above its calculated fair value: price C$1.25, fair value C$0.5100, a gap of about −59% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OGI?
No. The price is what the market pays today (C$1.25); the fair value is what the company's own numbers justify (C$0.5100). For OrganiGram Holdings Inc the two are C$0.7400 per share apart. That gap is exactly why we show both numbers side by side.
How much is OrganiGram Holdings Inc worth?
The market values OrganiGram Holdings Inc at about C$174M (market capitalisation, as of Nov 8, 2026). Per share that is C$1.25; our models calculate a fair value of C$0.5100 per share.
What do the bullish and bearish scenarios say about OGI?
Our models span a range for OrganiGram Holdings Inc: cautious scenario C$0.3400, base C$0.5100, optimistic C$0.6400 per share (as of Nov 8, 2026, price C$1.25). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of OGI?
OrganiGram Holdings Inc trades at a price-to-earnings ratio of 2.1 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of C$0.5100 is built from several models across several years. Other multiples: P/B 0.5, P/S 0.6, EV/EBITDA 9.7.
How solid is the balance sheet of OrganiGram Holdings Inc (OGI)?
Balance-sheet figures for OrganiGram Holdings Inc (as of Nov 8, 2026): return on equity 17.6%, debt of 0.20 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is OGI from its 52-week high?
OrganiGram Holdings Inc trades at C$1.25, about 57% below its 52-week high of C$2.90 and 2% above the low of C$1.23 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of C$0.5100 is for.
Which stocks are comparable to OrganiGram Holdings Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is OrganiGram Holdings Inc stock attractive at the current price?
The data as of Nov 8, 2026: price C$1.25, calculated fair value C$0.5100 (−59%), Quality Score 35/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OGI calculated?
We run OrganiGram Holdings Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of C$0.5100 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. OrganiGram Holdings Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of OrganiGram Holdings Inc (OGI)?
The closing price on Nov 6, 2026 was C$1.25. Our model-based fair value is C$0.5100, about 59% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with OrganiGram Holdings Inc right now?
The price sits above even our optimistic bull case (C$0.6400). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (C$0.3400 to C$0.6400) leaves room in how you read the outcome.

Key figures of OrganiGram Holdings Inc

How large is the market capitalisation of OrganiGram Holdings Inc (OGI)?
The market capitalisation of OrganiGram Holdings Inc is C$174M (≈ $123M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of OrganiGram Holdings Inc (OGI)?
The price-to-sales ratio of OrganiGram Holdings Inc is 0.56 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of OrganiGram Holdings Inc (OGI)?
Earnings per share at OrganiGram Holdings Inc are C$0.6000 (price ÷ EPS = P/E 2.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of OrganiGram Holdings Inc (OGI)?
The net margin of OrganiGram Holdings Inc is 28.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of OrganiGram Holdings Inc (OGI)?
The return on equity (ROE) of OrganiGram Holdings Inc is 17.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of OrganiGram Holdings Inc (OGI)?
On an EBIT basis the return on assets of OrganiGram Holdings Inc is −26.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of OrganiGram Holdings Inc (OGI)?
The operating margin of OrganiGram Holdings Inc is 5.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at OrganiGram Holdings Inc (OGI)?
Revenue at OrganiGram Holdings Inc is growing +49.4% versus a year earlier (3y avg +21.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does OrganiGram Holdings Inc (OGI) generate?
The free cash flow of OrganiGram Holdings Inc is −C$24.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does OrganiGram Holdings Inc (OGI) hold?
OrganiGram Holdings Inc holds more cash than debt, C$74.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch OrganiGram Holdings Inc in the live analysis

One click puts OrganiGram Holdings Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.